Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 14
- Registration Number
- NCT03463408
- Locations
- 🇺🇸
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, United States
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 4
- Registration Number
- NCT03461952
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition
- Conditions
- Interventions
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 150
- Registration Number
- NCT03453892
- Locations
- 🇩🇪
Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03449108
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-26
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 481
- Registration Number
- NCT03445533
- Locations
- 🇩🇪
Universitatsklinikum Regensburg, Regensburg, Germany
🇫🇷CHU Amiens Picardie - Hopital Sud, Amiens, France
🇺🇸Sutter Health Sacramento, Sacramento, California, United States
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
- Conditions
- Interventions
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT03442569
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2023-02-21
- Target Recruit Count
- 8
- Registration Number
- NCT03437200
- Locations
- 🇪🇸
Institut Catala d'Oncologia - ICO Badalona - Hospital De Mataro, Barcelona, Spain
🇪🇸Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia), Barcelona, Spain
🇫🇷Institut Gustave Roussy, Villejuif, France
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 5
- Registration Number
- NCT03425331
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Saint John's Cancer Institute
- Target Recruit Count
- 49
- Registration Number
- NCT03425292
- Locations
- 🇺🇸
Saint John's Cancer Institute, Santa Monica, California, United States
Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2024-01-09
- Target Recruit Count
- 9
- Registration Number
- NCT03420521
- Locations
- 🇺🇸
Johns Hopkins Medical Institution, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.